Want to see BMY full AI Analyst Report?
BMY Stock Chart & Stats
$57.54
-$0.43(-0.74%)
At close: 4:00 PM EDT
$57.54
-$0.43(-0.74%)
Day’s Range― - ―
52-Week Range$42.52 - $62.89
Previous CloseN/A
Volume8.00M
Average Volume (3M)12.81M
Market Cap
$118.32B
Enterprise Value$147.77B
Total Cash (Recent Filing)$10.49B
Total Debt (Recent Filing)$44.46B
Price to Earnings (P/E)16.2
Beta0.25
Next Earnings
Jul 30, 2026EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend Yield4.33%
Share Statistics
EPS (TTM)3.56
Shares Outstanding2,042,071,300
10 Day Avg. Volume12,257,255
30 Day Avg. Volume12,807,770
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit4.43
Enterprise Value/Ebitda10.75
Forecast
1Y Price Target
$63.67Price Target Upside10.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)6.33
Revenue Forecast (FY)$47.34B
Bulls Say, Bears Say
Bulls Say
Growth-portfolio MomentumA diversified growth portfolio (Eliquis, Breyanzi, Reblozyl, Camzyos, Sotyktu, Qvantig) delivering mid-to-high single-digit organic growth provides durable revenue engines. Multiple growing franchises reduce dependency on legacy brands and support sustained top-line resilience and reinvestment capacity.
Robust Cash GenerationStrong trailing free cash flow and operating cash flow underpin durable capital allocation flexibility, funding dividends, R&D and M&A. FCF near reported earnings (0.89x) shows conversion ability that supports strategic investment even while managing balance sheet obligations.
Pipeline Progress & R&D ProductivityRegulatory designations and positive Phase III interim results across programs increase approval probability and potential new revenue streams. Coupled with targets to speed lead identification and cut cycle times, this structurally improves pipeline throughput and long-term portfolio replenishment.
Bears Say
Elevated LeverageMaterial leverage limits financial flexibility and increases interest and refinancing risk. Although improved from prior highs, higher debt-to-equity versus earlier years constrains M&A optionality, makes the firm more sensitive to cash-flow shocks, and narrows strategic choices.
Concentrated Late‑stage ReadoutsA cluster of pivotal late‑stage trials in late‑2026 creates binary execution risk: adverse outcomes would materially dent the company’s growth trajectory. Reliance on several large readouts concentrates developmental risk and could meaningfully alter medium‑term revenue assumptions.
Margin Pressure & Generic ErosionProduct‑mix shifts, price reductions and ongoing generic competition on legacy brands are compressing gross margins. Sustained mix headwinds reduce operating leverage and long‑run free cash flow potential, challenging margin sustainability absent offsetting higher‑margin growth.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $42.52 and its highest was $62.89 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $118.32B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Apr 30, 2026. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.424 by $0.156.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Undervalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 4.33%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.6.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,042,071,300 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $1.58 in its last earnings report, beating expectations of $1.424. Following the earnings report the stock price went up 5.208%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$63.67 (10.65% Upside)
$63.67 (10.65% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.40%
12-Months-Change
Fundamentals
Return on Equity
39.05%
Trailing 12-Months
Asset Growth
-6.44%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
BMY Company Deck
BMY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted broad commercial momentum across the growth portfolio (9% growth) and several strong product performances (Eliquis +13%, Breyanzi +53%, Reblozyl +15%, Camzyos ~100%, Sotyktu +20%), along with multiple regulatory and clinical milestones (iberdomide priority review, positive mezignomide and ADC Phase III interim results) and a strong balance sheet (~$11B cash). Offsetting these positives were near-term headwinds including an 8% decline in Opdivo driven by wholesaler inventory dynamics, a 280 basis point gross margin decline due to product mix, continued generic pressures on legacy brands, and meaningful reliance on several late-2026 pivotal readouts that carry binary risk. On balance, the highlights materially outweigh the lowlights given diversified growth drivers, pipeline progress, reaffirmed guidance and financial flexibility, leading to a constructive outlook.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$63.67
▲(10.65% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
18.67% Mutual Funds
0.32% Other Institutional Investors
54.01% Public Companies and Individual Investors